Els Boone retweeted
#ESC2024 @escardio FAME 2: 10-year follow-up
🏪 PCI is 25% more likely to lead to better outcomes than medical therapy alone
🔑 48% of patients were tied. Nearly half the time, it won't make a big difference which one you choose.
@PCRonline @CoreAalst @CardioAalst @OptimaCTO
Els Boone retweeted
“Hot Line 4 is very important and will probably be the highlight of the Hot Lines for many cardiovascular health professionals. It includes a series of trials – ILUMIEN IV, OCTIVUS and OCTOBER..."
@LNAndreasen @h_evald @omeedneghabat @jcspratt #cardotwitter #octfirst
Get ready for #ESCCongress 2023 and discover the highlights from the Hot Line programme 🕒 bit.ly/3YIZeuf
#cardiology #cardionews
Els Boone retweeted
5-year follow up of DEFINE-FLAIR (iFR vs FFR-guided revascularisation) presented by @JEscaned #EuroPCR2023
➡️ MACE higher in iFR arm (HR 1.18; CI 0.99 - 1.41, p=0.07)
➡️ All-cause death 3% higher in iFR arm (HR 1.51; CI 1.22 - 2.90)
➡️ Difference driven by CV death
Els Boone retweeted
We’d like to take a moment acknowledge Drs. @DDamario, @Vale_Frittitta, and Antonio Greco for their commitment to personalized vascular care.
Thank you for sharing your innovative projects aimed at improving #cardiovascular care for patients at #EuroPCR: https://nitter.cf/t.co/YqPjDlo6z7
Els Boone retweeted
1/ COMBINE (OCT–FFR): Using OCT in DM to detect risk
FFR negative lesions, according to contemporary trial data, are very low risk for subsequent events. BUT...DM patients are a unique entity. What if we could use OCT, with its incredible resolution, to identify high risk - TCFA.
Els Boone retweeted
Are you prepared for the XIENCE short DAPT program? Stay tuned...coming soon @TCTConference @Drroxmehran @DLBHATTMD













